Skip to Main Content

When Michelle Dipp and Jennifer Lum decided to launch a life sciences growth equity fund two years ago, the market looked very different.

The Covid-19 pandemic was driving investors in droves to biotech and pharma companies. Automation and drug manufacturing were becoming hot topics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment